Cite
Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021;385(23):2140-2149doi: 10.1056/NEJMoa2109730.
Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., Olsha-Castell, S., Arad, D., Hasin, T., Levi, N., Asleh, R., Amir, O., Meir, K., Cohen, D., Dichtiar, R., Novick, D., Hershkovitz, Y., Dagan, R., Leitersdorf, I., Ben-Ami, R., Miskin, I., Saliba, W., Muhsen, K., Levi, Y., Green, M. S., Keinan-Boker, L., & Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. The New England journal of medicine, 385(23), 2140-2149. https://doi.org/10.1056/NEJMoa2109730
Mevorach, Dror, et al. "Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel." The New England journal of medicine vol. 385,23 (2021): 2140-2149. doi: https://doi.org/10.1056/NEJMoa2109730
Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, Olsha-Castell S, Arad D, Hasin T, Levi N, Asleh R, Amir O, Meir K, Cohen D, Dichtiar R, Novick D, Hershkovitz Y, Dagan R, Leitersdorf I, Ben-Ami R, Miskin I, Saliba W, Muhsen K, Levi Y, Green MS, Keinan-Boker L, Alroy-Preis S. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021 Dec 02;385(23):2140-2149. doi: 10.1056/NEJMoa2109730. Epub 2021 Oct 06. PMID: 34614328; PMCID: PMC8531987.
Copy
Download .nbib
